<DOC>
	<DOCNO>NCT03062384</DOCNO>
	<brief_summary>The purpose study evaluate use yeast-selenium supplement ( AT-001 ) safe elderly subject dementia , , see supplement improves test related brain health .</brief_summary>
	<brief_title>AT-001 Long-term Preservation Brain Health Aging</brief_title>
	<detailed_description>Double blind , placebo-controlled , single-center study . Approximately 40 healthy volunteer randomize study drug 20 healthy volunteer randomize placebo , total 60 enrol participant . All participant treat study drug placebo 12 month . Subjects see clinic follow visit : Screening ( Day -14 ) , Baseline ( Day 0 ) , Month 6 , End-of-Study ( Month 12 ) study drug . An additional safety visit Month 13 ( four week study drug discontinuation ) require participant . Participants undergo vital sign assessment , medical history review , medication list review , review Adverse Events ( AEs ) Serious Adverse Events ( SAEs ) visit . Participants undergo neuropsychological test routine physical examination screen , baseline , end-of-study visit . Participants undergo blood draw , urine collection , MRI ass lumbar puncture safety , lumbar puncture baseline end-of-study visit .</detailed_description>
	<criteria>Not demented DSMIV criterion . Englishspeaking , ensure compliance cognitive testing study visit procedure . Montreal Cognitive Assessment ( MoCA ) score screen visit ≥24/30 . Female participant must pregnant childbearing potential ( surgically sterile postmenopausal &gt; 1 year ) . Stable medical condition 3 month prior screen visit opinion study physician . Nondiabetic , confirm fast serum glucose &lt; 120 mg/dL oral hypoglycemic agent insulin treatment . No clinically significant abnormality labs ( CBC , chemistry panel , PT/INR , aPTT , urinalysis ) . Stable medication 4 week prior screen . Able ingest oral medication . Physically acceptable study confirm medial history , physical exam , neurological exam , clinical test opinion study physician . Significant neurological disease , Parkinson 's disease , brain tumor , multiple sclerosis , seizure disorder Major depression past 12 month ( DSMIV criterion ) , major mental illness schizophrenia , recent ( past 12 month ) alcohol substance abuse . History invasive cancer within past 2 year ( exclude nonmelanoma skin cancer ) . Contraindications lumbar puncture ( bleed disorder , platelet count &lt; 100,000 , anticoagulant treatment , major structural abnormality sepsis area lumbosacral spine , previous low back surgery would make LP technically difficult opinion study physician , hypersensitivity lidocaine ) . Contraindications MRI ( pacemaker , shrapnel , metallic implant , etc ) . Clinically significant abnormality labs ( CBC , chemistry panel , PT/INR , aPTT , urinalysis ) . Use investigational agent within 30 day prior screen . Major surgery within eight week prior Baseline Visit . Severe unstable major medical illness , include uncontrolled cardiac condition heart failure ( New York Heart Association Class III IV ) . Antiretroviral therapy human immunodeficiency virus ( HIV ) . Residence skilled nursing facility . Blindness , deafness , language difficulty , disability may prevent participant . Excluded Medications : Experimental drug . Coumadin , heparin , anticoagulant . Insulin hypoglycemic agent . Supplements contain 50 µg selenium/day ( US RDA ) 12 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>brain</keyword>
	<keyword>health</keyword>
</DOC>